Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...

AdvaMed, the MedTech Association, released its AI Policy Roadmap (the Roadmap) outlining policy priorities for Congress and the U.S. Food and Drug Administration (FDA).

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

AI adoption in pharma can be slow, but failing to scale these new tools across your organization is a missed opportunity.

The unintentional theme of today’s issue is the struggle for control over how we implement AI in the U.S. On one side, where ...

There could be an upside to incorporating AI for the FDA. Using AI to assist in final drug reviews would "represent a chance ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

Looking Ahead The FDA’s full-scale adoption of AI technology represents a leap forward in regulatory oversight. By ...

Discover how AI is transforming healthcare with insights from Microsoft leaders on AI advancements, success stories, and ...

Experts have cautioned against adopting the technology too quickly for clinical purposes. The first meeting of FDA’s Digital ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement generative artificial intelligence ...

Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.